29 results on '"Roman-Torres, Karisse"'
Search Results
2. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis
3. Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden
4. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
5. MPN-145 Retrospective Analysis of Anemia Benefit of Pacritinib From the PERSIST-2 Trial
6. MPN-141 Retrospective Comparison of Patient Outcomes on Pacritinib Versus Ruxolitinib in Patients With Myelofibrosis and Thrombocytopenia
7. Differential Impact of Thrombocytopenia and Anemia on Myelofibrosis (MF) Symptom Burden
8. Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis
9. MPN-499 A Retrospective Analysis of Pacritinib Treatment Outcomes in Myelofibrosis Patients With and Without Monocytosis
10. MPN-497 Impact of Pacritinib on Symptoms in Thrombocytopenic Myelofibrosis Patients Who Require Red Blood Cell Transfusion
11. MPN-470 Efficacy of Pacritinib in Patients With Myelofibrosis Who Have Both Thrombocytopenia and Anemia
12. Efficacy of Pacritinib in Patients With Myelofibrosis Who Have Both Thrombocytopenia and Anemia
13. A Retrospective Analysis of Pacritinib Treatment Outcomes in Myelofibrosis Patients With and Without Monocytosis
14. Impact of Pacritinib on Symptoms in Thrombocytopenic Myelofibrosis Patients Who Require Red Blood Cell Transfusion
15. Impact of Symptom Benefit and Transfusion Response on Survival in Myelofibrosis Patients Treated with Pacritinib: PERSIST-2 Landmark Survival Analysis
16. Retrospective Analysis of the Relationship between Transfusion Independence and Bone Marrow Fibrosis Reduction in Patients with Myelofibrosis Treated with Pacritinib Versus Ruxolitinib
17. Platelet Response in Pacritinib-Treated Patients with Cytopenic Myelofibrosis: A Retrospective Analysis of PERSIST-2 and PAC203 Studies
18. MPN-339 Outcomes of Patients With Myelofibrosis and Elevated Peripheral Blood Blasts Treated With Pacritinib on Phase II/III Trials
19. MPN-111 SVR (Spleen Volume Reduction) Predicts OS (Overall Survival) in MF (Myelofibrosis) Patients on PAC (Pacritinib) but Not BAT (Best Available Therapy): PERSIST-2 Landmark OS Analysis
20. MDS-460 Efficacy of Pacritinib for Spleen, Symptoms, and Anemia Benefit in Myelofibrosis Patients Across the Cytopenic Spectrum
21. POSTER: MPN-339 Outcomes of Patients With Myelofibrosis and Elevated Peripheral Blood Blasts Treated With Pacritinib on Phase II/III Trials
22. POSTER: MPN-111 SVR (Spleen Volume Reduction) Predicts OS (Overall Survival) in MF (Myelofibrosis) Patients on PAC (Pacritinib) but Not BAT (Best Available Therapy): PERSIST-2 Landmark OS Analysis
23. POSTER: MDS-460 Efficacy of Pacritinib for Spleen, Symptoms, and Anemia Benefit in Myelofibrosis Patients Across the Cytopenic Spectrum
24. Safety Analysis of Pacritinib in Patients with Myelofibrosis and Severe Thrombocytopenia
25. A Retrospective Head-to-Head Comparison between Pacritinib and Ruxolitinib in Patients with Myelofibrosis and Moderate to Severe Thrombocytopenia
26. The Impact of Pacritinib on Myelofibrosis Symptoms in Patients with Moderate and Severe Thrombocytopenia: A Retrospective Analysis of Patients in the Persist-2 Study
27. Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies
28. Poster: MPN-141 Retrospective Comparison of Patient Outcomes on Pacritinib Versus Ruxolitinib in Patients With Myelofibrosis and Thrombocytopenia
29. Poster: MPN-145 Retrospective Analysis of Anemia Benefit of Pacritinib From the PERSIST-2 Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.